Skip to content
The Nexus
DossierENTITY

Dr. Rituparna Das

Coverage of Dr. Rituparna Das in the Nexus archive.

Earliest in view: Jun 18 · 20:11 UTCMost recent: Jun 18 · 20:11 UTC
Co-mentioned in this coverage
FDAorganization1Modernaorganization1mFlusivatopic1mRNA technologytopic1Influenzatopic1Dr. Flor Munoz-Rivasperson1Dr. Anna Durbinperson1Dr. Timothy Brennanperson150-64 age grouptopic165+ age grouptopic1
Recent coverage
  • HEALTHJun 18 · 20:11 UTCWPLG LOCAL 10 MIAMI
    FDA panel backs first-of-its-kind flu vaccine using mRNA technology

    An FDA panel recommended approval of Moderna's first mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older, citing its benefits outweighing risks. The vaccine, developed using technology similar to COVID-19 vaccines, showed a 27% reduction in flu cases compared to traditional vaccines in clinical trials and is under final FDA review for potential approval by August.

Dr. Rituparna Das · Dossier · The Nexus